COMMUNIQUÉS West-GlobeNewswire

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
05/05/2026
Successfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of 42.2% for 150 mg dose (p=0.018) and 42.9% for 300 mg dose (p=0.015) at Week 16, which are the highest rates observed [...]
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
05/05/2026
U.S. Launch of MYQORZO ® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maximal Exercise [...]
Supernus Announces First Quarter 2026 Financial Results
05/05/2026
Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter [...]
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
05/05/2026
– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) – – Additional data from VIRAGE Phase 2b clinical trial of [...]
EPIK Biosciences Launches to Pioneer Ketamine-Powered Psychedelic Therapies to Transform Treatment of Mental Health, Pain, and Addiction
05/05/2026
Advancing synergistic combination medicines, non-opioid solutions for chronic pain, neuropsychiatric disorders, and substance use disorders using patient-friendly delivery methods. AUSTIN, Texas, May 05, 2026 (GLOBE [...]
HealthEquity Announces First Quarter Earnings Release Date and Investor Conference Schedule
05/05/2026
DRAPER, Utah, May 05, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in [...]
Hyperion DeFi Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
05/05/2026
DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced that it intends to [...]
FDA Expands Market Access, Authorizes New ENDS Products
05/05/2026
White Oak, Md., May 05, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product [...]
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
05/05/2026
First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R [...]
Sienna Reports First Quarter 2026 Financial Results and Continues Platform Expansion
05/05/2026
MARKHAM, Ontario, May 05, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three months ended March 31, 2026. Highlights Average [...]
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
05/05/2026
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
05/05/2026
Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test. First quarter 2026 test volume reflects 13% and 7 [...]
Korro to Participate in Upcoming Investor Conferences
05/05/2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class [...]
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
05/05/2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and [...]
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
05/05/2026
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Claseprubart granted Orphan Drug [...]
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
05/05/2026
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation [...]
Cytokinetics Announces Proposed Public Offering of Common Stock
05/05/2026
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million of shares of its [...]
STERIS Announces Dividend of $0.63 per share
05/05/2026
DUBLIN, IRELAND, May 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on [...]
Dentsply Sirona Reports First Quarter 2026 Results
05/05/2026
News Summary Reported net sales of $880 million Delivered GAAP gross margin of 48.5% , GAAP net loss per share of ($0.05) Achieved adjusted gross margin of 50.7% , adjusted EBITDA margin of 14.7% , adjusted EPS of $0.27 [...]

Pages